Modality
ADC
MOA
IL-23i
Target
MET
Pathway
NF-κB
RBLGS
Development Pipeline
Preclinical
Jun 2024
→ May 2028
PreclinicalCurrent
NCT08642128
2,390 pts·LGS
2024-06→2028-05·Not yet recruiting
2,390 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-05-052.1y awayInterim· LGS
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Preclinical
Not yet…
Catalysts
Interim
2028-05-05 · 2.1y away
LGS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08642128 | Preclinical | LGS | Not yet recr... | 2390 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| Tirasotorasib | Viking Therapeutics | Phase 1 | CFTR | |
| Talazasiran | Kymera | NDA/BLA | MET | |
| STO-2663 | Stoke Ther | Approved | LAG-3 |